CryoLife CE-marks tissue-engineered graft:
This article was originally published in Clinica
Executive Summary
CryoLife has CE-marked for sale in Europe its tissue-engineered vascular graft for dialysis access and peripheral vascular reconstruction. The SynerGraft model 100 graft is based on the Atlanta, Georgia's firm's SynerGraft technology, which centres around the removal of antigens from human and/or animal tissue leaving a collagen matrix that has the potential to be repopulated with the patient's own cells.
You may also be interested in...
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.
Roche Gets Adjuvant ALK+ Lung Cancer To Itself With Alecensa Approval
The US FDA cleared Roche’s supplemental approval request for ALK inhibitor Alecensa in ALK-positive non-small cell lung cancer following tumor resection.